Medical treatment of Cushing's syndrome: Adrenal-blocking drugs and ketaconazole

Neuroendocrinology

Volumn 92, Issue SUPPL. 1, 2010, Pages 111-115

  Feelders, Richard A ^a   Hofland, Leo J ^a   De Herder, Wouter W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Adrenal blocking drugs; Cushing's syndrome; Medical treatment

Indexed keywords

AMINOGLUTETHIMIDE; ANDROGEN; CABERGOLINE; CORTICOTROPIN; ETOMIDATE; HYDROCORTISONE; KETOCONAZOLE; METYRAPONE; MINERALOCORTICOID; MITOTANE; PASIREOTIDE;

ACNE; ACTH SECRETING ADENOMA; ADRENAL CORTEX ADENOMA; ADRENALECTOMY; ANDROGEN BLOOD LEVEL; CONFERENCE PAPER; CORTICOTROPIN RELEASE; CUSHING SYNDROME; DRUG INDICATION; ECTOPIC CORTICOTROPIN PRODUCTION; GASTROINTESTINAL SYMPTOM; HIRSUTISM; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE RELEASE; HYPERTENSION; HYPOGONADISM; HYPOPHYSECTOMY; LIVER TOXICITY; NEUROTOXICITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SIDE EFFECT; STEROIDOGENESIS;

CUSHING SYNDROME; ENZYME INHIBITORS; ETOMIDATE; HUMANS; KETOCONAZOLE; METYRAPONE; MITOTANE;

EID: 77956515048     PISSN: 00283835     EISSN: None     Source Type: Journal    
DOI: 10.1159/000314292     Document Type: Conference Paper

References (25)

1. Biller BM, Grossman AB, Stewart PM, et al: Treatment of adrenocorticotropin-depen-dent Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 2008; 93: 2454-2462.
2. Morris D, Grossman A: The medical management of Cushing's syndrome. Ann NY Acad Sci 2002; 970:119-133.
3. Sonino N, Zielezny M, Fava GA, Fallo F, Boscaro M: Risk factors and long-term outcome in pituitary-dependent Cushing's disease. J Clin Endocrinol Metab 1996; 81: 2647-2652.
4. Atkinson AB, Kennedy A, Wiggam MI, Mc-Cance DR, Sheridan B: Long-term remission rates after pituitary surgery for Cushing's disease: the need for long-term surveillance. Clin Endocrinol (Oxf) 2005; 63: 549-559.
5. Patil CG, Prevedello DM, Lad SP, Vance ML, Thorner MO, Katznelson L, Laws ER Jr: Late recurrences of Cushing's disease after initial successful transsphenoidal surgery. J Clin Endocrinol Metab 2008; 93: 358-362.
6. Estrada J, Boronat M, Mielgo M, Magallon R, Millan I, Diez S, Lucas T, Barcelo B: The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing's disease. N Engl J Med 1997; 336: 172-177.
7. Newell-Price J, Bertagna X, Grossman AB, Nieman LK: Cushing's syndrome. Lancet 2006; 367:1605-1617.
8. Dekkers OM, Biermasz NR, Pereira AM, Roelfsema F, Van Aken MO, Voormolen JH, Romijn JA: Mortality in patients treated for Cushing's disease is increased, compared with patients treated for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab 2007; 92:976-981.
9. Lacroix A: ACTH-independent macronodu-lar adrenal hyperplasia. Best Pract Res Clin Endocrinol Metab 2009; 23: 245-259.
10. Young RB, Bryson MJ, Sweat ML, Street JC: Complexing of DDT and o,p'DDD with adrenal cytochrome P-450 hydroxylating systems. J Steroid Biochem 1973; 4: 585-591.
11. Luton JP, Mahoudeau JA, Bouchard P, Thie-blot P, Hautecouverture M, Simon D, Laudat MH, Touitou Y, Bricaire H: Treatment of Cushing's disease by o,p'DDD. Survey of 62 cases. N Engl J Med 1979; 300:459-464.
12. Lamberts SW, Bons EG, Bruining HA, De Jong FH: Differential effects of the imidazole derivatives etomidate, ketoconazole and mi-conazole and of metyrapone on the secretion of cortisol and its precursors by human ad-renocortical cells. J Pharmacol Exp Ther 1987; 240: 259-264.
13. Drake WM, Perry LA, Hinds CJ, Lowe DG, Reznek RH, Besser GM: Emergency and prolonged use of intravenous etomidate to control hypercortisolemia in a patient with Cushing's syndrome and peritonitis. J Clin Endocrinol Metab 1998; 83:3542-3544.
14. Carballeira A, Fishman LM, Jacobi JD: Dual sites of inhibition by metyrapone of human adrenal steroidogenesis: correlation of in vivo and in vitro studies. J Clin Endocrinol Metab 1976; 42:687-695.
15. Verhelst JA, Trainer PJ, Howlett TA, Perry L, Rees LH, Grossman AB, Wass JA, Besser GM: Short and long-term responses to me-tyrapone in the medical management of 91 patients with Cushing's syndrome. Clin En-docrinol (Oxf) 1991; 35: 169-178.
16. Engelhardt D, Weber MM, Miksch T, Abedinpour F, Jaspers C: The influence of ketoconazole on human adrenal steroido-genesis: incubation studies with tissue slices. Clin Endocrinol (Ox f) 1991; 35: 163-168.
17. Sonino N: The use of ketoconazole as an inhibitor of steroid production. N Engl J Med 1987; 317:812-818.
18. Sonino N, Boscaro M, Paoletta A, Mantero F, Ziliotto D: Ketoconazole treatment in Cush-ing's syndrome: experience in 34 patients. Clin Endocrinol (Oxf) 1991; 35: 347-352.
19. Tabarin A, Navarranne A, Guerin J, Corcuff JB, Parneix M, Roger P: Use of ketoconazole in the treatment of Cushing's disease and ec-topic ACTH syndrome. Clin Endocrinol (Oxf) 1991; 34: 63-69.
20. Castinetti F, Morange I, Jaquet P, Conte-Devolx B, Brue T: Ketoconazole revisited: a preoperative or postoperative treatment in Cushing's disease. Eur J Endocrinol 2008; 158:91-99.
21. Stalla GK, Stalla J, Huber M, Loeffler JP, Hollt V, von Werder K, Muller OA: Ketocona-zole inhibits corticotropic cell function in vitro. Endocrinology 1988; 122:618-623.
22. De Bruin C, Pereira AM, Feelders RA, Romijn JA, Roelfsema F, Sprij-Mooij DM, Van Aken MO, Van Der Lelij AJ, De Herder WW, Lamberts SW, Hofland LJ: Coexpres-sion of dopamine and somatostatin receptor subtypes in corticotroph adenomas. J Clin Endocrinol Metab 2009; 94: 1118-1124.
23. Boscaro M, Ludlam WH, Atkinson B, Glus-man JE, Petersenn S, Reincke M, Snyder P, Tabarin A, Biller BM, Findling J, Melmed S, Darby CH, Hu K, Wang Y, Freda PU, Grossman AB, Frohman LA, Bertherat J: Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand soma-tostatin analog pasireotide (SOM230): a mul-ticenter, phase II trial. J Clin Endocrinol Metab 2009; 94: 115-122.
24. Pivonello R, De Martino MC, Cappabianca P, De Leo M, Faggiano A, Lombardi G, Hof-land LJ, Lamberts SW, Colao A: The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab 2009; 94: 223-230.
25. Feelders RA, De Bruin C, Pereira AM, Romijn JA, Netea-Maier RT, Hermus AR, Zelissen PM, De Jong FH, Van Der Lely AJ, De Herder WW, Hofland LJ, Lamberts SW: Stepwise medical treatment of Cushing's disease with pasireotide mono-or combination therapy with cabergoline and low-dose keto-conazole. N Engl J Med 2010;362:1846-1848.